Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2) . Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research[1][2]. The component ratio of this product is Active ingredient : Excipients = 9 : 47.